What's Hot
View all perspectives
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 6 months ago
Can we identify 1st Trimester predictors of adverse pregnancy outcome (APO) in #lupus? Dr Larosa studied women in 🇫🇷 (N=238; 98% on #HCQ; 86% had SLEDAI=0). 34(14%) had APO. Higher SLICC damage and LAC+ve predicted APO but not LLDAS/DORIS Remission #EULAR2021 #OP0295 @RheumNow https://t.co/423sSEKLFY
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 6 months ago
Why do black women with #lupus have poor #HRQoL? Dr Kimble used untargeted metabolomic profiling in N=23 black women SLE and N=21 black women nonSLE. The former had profiles consistent with⬇️energy production resulted in ⬆️fatigue and other symptoms #EULAR2021 #POS0173 @RheumNow https://t.co/GYzmpf8GwW
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 6 months ago
More novel target (IL23-i; Risankizumab) for #psoriaticarthritis👏. Dr Ostor presented results from Phase III KEEPsAKE2. 46% of patients were Bio-IR. 51.3% of RZB-treated vs 26.5% Placebo-tx achieved ACR20 response at 6mo (p<0.001). No major safety #EULAR2021 #OP0228 @RheumNow https://t.co/6AIGCNMApv
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 6 months ago
Is Dissociation a component of #lupus brain fog ☁️? Dr Monahan administered DES scale (score =>25 = Dissociation) to N=339 pts; of which 97 (27%) had NPSLE. Only 13% had abnormal score. No difference in score btw NPSLE vs non-NPSLE #EULAR2021 #POS0709 @RheumNow https://t.co/aarL8gdCDM
Robert B Chao, MD doctorRBC
3 years 6 months ago
Israeli study of all cause mortality in PsA vs general population
⭐️no increased mortality in PsA group
⭐️leading causes of death was cancer in both groups
⭐️age, male sex, BMI, socioeconomic status, PsO associated with ⬆️mortality, NOT DMARDs
Abs#OP0219
#EULAR2021 @RheumNow
Richard Conway RichardPAConway
3 years 6 months ago
Dr Bilgin presents on PLEX in AAV. I'm not a believer post-PEXIVAS despite attempts to slice and dice that data and this seems to show no evidence to change my mind @RheumNow #EULAR2021 Abstr#POS0255 https://t.co/U3zwt619lc
Paul Studenic Stiddyo
3 years 6 months ago
#POS0221 retrospective propensity score corrected observational study TOFA (n:156) vs. BARI (n:138): week 24: CDAI REM (see pic) BARI>TOFA. Factors of treatment resistence in TOFA: OR: Nr of prior bDMARD 1.77 & HAQ-DI 18.6
No such factors in BARI identified.
#EULAR2021 @RheumNow https://t.co/u9Nati2ZJO
Dr. John Cush RheumNow
3 years 6 months ago
Is Rituximab and Belimumab the Combination to Beat Lupus? by Dr. Eric Dein (@ejdein1) #EULAR2021
On day 2 of EULAR , Dr. Michael Ehrenstein presented OP0129, a presentation on the BEAT-LUPUS trial looking at belimumab therapy after rituximab.
https://t.co/r4aNG7KR5h https://t.co/nppgRytnlr
Meral K. El Ramahi, MD MeralElRamahiMD
3 years 6 months ago
➡️Percentage achieving PASI75 (not H2H comparison):
⭐️GUS > IXE > INF > SEC > UST > GOL 100mg >ADA> CTZ > TOFA> GOL 50 mg > ETN > APR
⭐️Amongst TNFi (not H2H): INF > GOL > ADA > CTZ > ETN
Great talk by Dr. L Coates on personalized tx approach for PsA.
#EULAR2021 @RheumNow https://t.co/jMGaBlg3Iy
Meral K. El Ramahi, MD MeralElRamahiMD
3 years 6 months ago
➡️%age achieving ACR20 (not H2H comparisons):
⭐️GUS > IXE > TOFA > CTZ > ETN > INF > ADA > SEC > GOL > UST > APR
➡️ Choosing therapies in AxSpA:
⭐️TNFi (ADA), IL17i (SEC), Jaki (UPA); however, axPsA may be different than AxSpA. Need more trials to assess!
#EULAR2021 @RheumNow https://t.co/toMyS3uPAZ
Meral K. El Ramahi, MD MeralElRamahiMD
3 years 6 months ago
How to choose therapy for psoriatic dz?
➡️Should be a personalized approach based on co-morbidities
➡️Below drugs are approved for primary therapy of co-morbid condition:
⭐️IBD: SSZ, ADA, INF. GOL for UC, UST for Crohn's
⭐️Uveitis: GCs & INF preferred, ADA
#EULAR2021 @RheumNow https://t.co/inN07QP9t4
Meral K. El Ramahi, MD MeralElRamahiMD
3 years 6 months ago
Step-wise vs rapid escalator approach for PsO & PsA?
⭐️CONTROL study:
➡️bDMARD-naive active PsA w/ IR to MTX for at least 4w randomized to ADA+MTX vs escalated MTX (avg dose 21.8 mg/wk, 55% PO, 36% SQ)
➡️41.5% MDA at wk 16 w/ ADA+MTX vs 13.1%
#EULAR2021 @RheumNow https://t.co/uw5BFQGqNV
Ashima Makol MD AshimaMakol
3 years 6 months ago
❗️Dismal trend in #scleroderma survival ➡️38 y data from @Olmstedcounty
An URGENT call for better therapeutics
👉 2.5 fold>general population
👉 NO trend for improved survival
👉 Age, Smoking, Digital Ischemia, ILD and PAH
Check out 👉POS0838 #EULAR2021 #CaitrinCoffey https://t.co/KDStYRI6nz
Robert B Chao, MD doctorRBC
3 years 6 months ago
Osteoarthritis related bio markers associated with MRI imaging biomarkers
⭐️COMP and MMP-3 negatively associated with knee cartilage thickness
⭐️serum biomarkers could predict future MRI based markers
Abs#POS0129
#EULAR2021 @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD
3 years 6 months ago
If a patient w/ PsA has high disease activity, would you take the rapid escalator approach (bDMARD) or a step-wise approach (csDMARD to start & escalate per response)?
Be sure to check out Dr. L Coates great talk on personalized tx approach! #EULAR2021 @RheumNow @ElaineHusniMD
Poster Hall